1. JC Biotech full ownership - The company bought the remaining 4.28% of JC Biotech for ₹7.98 cr, taking it to 100%. JC Biotech's FY26 revenue rose from ₹60 cr to ₹72.8 cr with EBITDA up from ₹7 cr to ₹9.2 cr, so full ownership now flows entirely to shareholders.
2. Nashik R&D centre - The ₹50 cr R&D centre (part of a ₹123 cr capex plan) is expected to become functional in the next quarter, with first-phase capacity planned to triple. It accelerates new products beyond Serratiopeptidase and supports industrial enzyme applications, addressing the pipeline bottleneck.
3. Fermentation capacity expansion - Utilisation has risen to 70-75% from 55-60%, and management will decide on capex next quarter, with infrastructure ready for an immediate 50% capacity increment. The \~₹50 cr expansion planned for FY28-29 removes the main capacity constraint as utilisation approaches 80%.
4. EFSA and US FDA approvals - Two EFSA food enzyme dossiers and three US FDA GRAS dossiers were filed in FY26; 13 of 17 EFSA dossiers have positive opinions. Anti-inflammatory products filed two years ago in Europe could get approval during FY27, making the company the only supplier for five to ten years.
5. SciTech effervescent expansion - Specialized Manufacturing revenue hit ₹20.1 cr in Q1 FY27, up 41% YoY, at 11% of total revenue. The 51% subsidiary is exploring disinfectants, cosmetics and textile washing applications, with FY26 revenue up 23% to ₹66.8 cr.
6. Animal Nutrition registrations - FY26 revenue grew 25% to ₹94.6 cr, driven by commercialisation of long-term registrations in Asian markets. The company plans to expand sales teams across USA, MENA and Asia and appoint new distributors, extending a growth streak that reached 22% YoY in Q3 FY26.
7. Food business baking and dairy - Food Processing revenue grew 19% to ₹96.7 cr in FY26, with Q1 FY27 food revenue up 51% YoY. Management calls the growth sustainable, not one-time, and is expanding beyond baking into high-protein dairy products under trial.
8. US branding strategy - Management expects 8-10% US growth as branding most products makes the business sticky. US subsidiary AEU earned ₹78.4 cr PAT on ₹212.2 cr revenue in FY26, and US margins run higher than India's due to customised formulation.
9. Probiotics portfolio expansion - Probiotics revenue reached ₹21.6 cr in FY26, with the approach shifting from commodity products to solutions. New launches target immunity, gut health and animal feed, in an Indian market projected to grow at 17% CAGR to 2034.
10. Biocatalysis commercialisation - FY26 revenue rose from ₹17.4 cr to ₹24.7 cr, with products under plant-level trials by API manufacturers. Management expects good growth in H2 FY27, and a patent on pharmaceutical biocatalysis applications was filed.